Compare · DRTS vs SYK
DRTS vs SYK
Side-by-side comparison of Alpha Tau Medical Ltd. (DRTS) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRTS and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $108.02B, about 86.5x DRTS ($1.25B).
- SYK has been more active in the news (8 items in the past 4 weeks vs 1 for DRTS).
- SYK has more recent analyst coverage (25 ratings vs 7 for DRTS).
- Company
- Alpha Tau Medical Ltd.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $1.25B
- $108.02B
- 1M return
- -
- +5.42%
- 1Y return
- -
- -19.96%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 8
- Recent ratings
- 7
- 25
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest DRTS
- Alpha Tau to Participate in October Investor Conferences
- Alpha Tau to Participate in September Investor Conferences
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
- Chief Financial Officer Levy Raphi exercised 2,871 units of Ordinary Shares at a strike of $2.98 and sold $43,073 worth of Ordinary Shares (2,871 units at $15.00) (SEC Form 4)
- Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
- Chief Financial Officer Levy Raphi exercised 17,730 units of Ordinary Shares at a strike of $2.98 and sold $248,277 worth of Ordinary Shares (17,730 units at $14.00) (SEC Form 4)
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)